What is ivacaftor, and what does it treat?
Ivacaftor (marketed as Kalydeco) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used for certain people with cystic fibrosis (CF). It works by improving the function of specific CFTR proteins rather than treating CF across all genetic types.
Which CFTR mutations can benefit from ivacaftor?
Ivacaftor is prescribed only for CF patients whose mutations are known to respond to a CFTR potentiator. In practice, clinicians choose ivacaftor based on the person’s CFTR genotype from genetic testing, because not all CFTR mutations improve with potentiation.
How is ivacaftor taken, and what factors affect dosing?
Dosing depends on patient age and weight, and it may also be adjusted based on drug interactions. People taking strong inhibitors or inducers of the drug-metabolizing enzyme CYP3A may need different dosing or extra monitoring, since these can change ivacaftor blood levels.
What side effects do people commonly report?
Common side effects can include headache, dizziness, nausea, vomiting, diarrhea, rash, and fatigue. Ivacaftor can also affect liver enzymes, so liver function monitoring is typically part of treatment for people starting or continuing therapy.
What monitoring is needed during treatment?
Clinicians generally monitor liver function tests during therapy, especially early on or in people with existing liver disease. If symptoms suggest liver problems (such as jaundice or persistent nausea), clinicians may check labs sooner.
Is ivacaftor used alone or with other CF medicines?
Ivacaftor can be used in combination regimens for some patients depending on their mutation and treatment plan. In CF care, combination use matters because different CFTR modulators target different problems in the CFTR protein (for example, reducing misfolding versus improving channel opening).
How does ivacaftor compare with other CFTR modulators?
Ivacaftor is a potentiator, so it targets how well the CFTR channel works. Other CFTR modulators can target different mechanisms (such as correcting CFTR folding or improving its processing). Which one is best depends on the person’s mutation and whether a drug matches the CFTR defect.
What patients ask most: does it help my lung symptoms?
People who have CF and a CFTR mutation that responds to ivacaftor may see improvements in lung-related outcomes and overall health measures, but the size of benefit varies by genotype and baseline disease.
What happens if someone stops taking ivacaftor?
If ivacaftor is stopped, the CFTR function improvement it provides typically decreases over time. Clinicians usually reassess symptoms and lung status, and they may consider alternative CFTR-modulator options if appropriate.
Sources
I’m missing the “provided information” you mentioned. If you paste the text or link(s) you want me to use, I’ll answer ivacaftor using only that material and add precise citations.